Edition:
United States

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

25.56USD
17 Nov 2017
Change (% chg)

$-0.20 (-0.78%)
Prev Close
$25.76
Open
$25.53
Day's High
$25.92
Day's Low
$25.31
Volume
124,128
Avg. Vol
170,320
52-wk High
$60.98
52-wk Low
$21.41

Chart for

About

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in... (more)

Overall

Beta: 4.31
Market Cap(Mil.): $739.46
Shares Outstanding(Mil.): 28.93
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 197.02 15.79
EPS (TTM): -- -- --
ROI: -- -10.12 12.01
ROE: -- -37.71 15.91

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

Nov 09 2017

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

Nov 06 2017

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

Oct 23 2017

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

Aug 29 2017

BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement

* ‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​

Aug 28 2017

BRIEF-Five Prime Therapeutics Q2 loss per share $1.58

* Five Prime announces second quarter 2017 results and provides business update

Aug 08 2017

BRIEF-Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018

* Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development

Jul 17 2017

BRIEF-Five Prime Therapeutics says Lewis Williams to be chairman of board in 2018

* Five Prime Therapeutics announces Lewis T. "Rusty" Williams plans to transition from CEO to executive chairman of the board in 2018

Jun 21 2017

BRIEF-Protagonist Therapeutics appoints Five Prime Therapeutics CEO to board of directors

* Protagonist Therapeutics appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its board of directors Source text for Eikon: Further company coverage:

Jun 08 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,678 +15.00
Novartis AG (NOVN.S) CHF83.30 +0.90
AstraZeneca plc (AZN.L) 4,975.00 --
Eli Lilly and Co (LLY.N) $82.89 -0.55
ArQule, Inc. (ARQL.OQ) $1.42 +0.09

Earnings vs. Estimates